Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Sunesis Pharmaceuticals (NASDAQ:SNSS) has received an alarming one-star ranking.

With that in mind, let's take a closer look at Sunesis and see what CAPS investors are saying about the stock right now.

Sunesis facts

Headquarters (founded)

South San Francisco, Calif. (1998)

Market Cap

$280.8 million



Trailing-12-Month Revenue

$5.7 million


CEO Daniel Swisher Jr. (since 2004)
CFO Eric Bjerkholt (since 2004)

Return on Capital (average, past 3 years)



$61.0 million / $23.8 million


Corden Pharma Switzerland LLC

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 30% of the 96 members who have rated Sunesis believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bear case for our ommunity:

Sunesis seems to have settled into a tight trading range since March, and I see [$5.50 per share] as a good trigger to set an underperform so as to take maximal advantage of the fluctuations. I'll likely stick with red thumbs because I think the stock is massively overvalued considering the negative implications of the 2012 interim analysis, which I delineated in one of my previous underperform pitches. As of now, topline data from the VALOR trial is expected in H1 2014 and I'm hoping for a huge upward run that will make puts enormously profitable.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.